Magnetic resonance nanoparticles for cardiovascular molecular imaging and therapy

References

• Hamilton A, Huang SL, Warnick D et al. Left ventricular thrombus enhancement after intravenous injection of echogenic immunoliposomes: studies in a new experimental model. Circulation 105, 2772–2778 (2002).
   PubMed Web of Science ®Google Scholar
• Unger EC, McCreery TP, Sweitzer RH, Shen D, Wu G. In vitro studies of a new thrombus-specific ultrasound contrast agent. Am. J. Cardiol. 81, 58G–61G (1998).
   PubMed Web of Science ®Google Scholar
• Marmottant P, Hilgenfeldt S. Controlled vesicle deformation and lysis by single oscillating bubbles. Nature 423, 153–156 (2003).
   PubMed Web of Science ®Google Scholar
• Unger EC, McCreery TP, Sweitzer RH, Caldwell VE, Wu Y. Acoustically active lipospheres containing paclitaxel: a new therapeutic ultrasound contrast agent. Invest. Radiol. 33, 886–892 (1998).
   PubMed Web of Science ®Google Scholar
• Alkan-Onyuksel H, Demos SM, Lanza GM et al. Development of inherently echogenic liposomes as an ultrasonic contrast agent. J. Pharm. Sci. 85, 486–490 (1996).
   PubMed Web of Science ®Google Scholar
• Demos SM, Alkan-Onyuksel H, Kane BJ et al. In vivo targeting of acoustically reflective liposomes for intravascular and transvascular ultrasonic enhancement. J. Am. Coll. Cardiol. 33, 867–875 (1999).
   PubMed Web of Science ®Google Scholar
• Wharton T, Wilson LJ. Highly-iodinated fullerene as a contrast agent for x-ray imaging. Bioorg. Med. Chem. 10, 3545–3554 (2002).
   PubMed Web of Science ®Google Scholar
• Cagle DW, Kennel SJ, Mirzadeh S, Alford JM, Wilson LJ. In vivo studies of fullerene-based materials using endohedral metallofullerene radiotracers. Proc. Natl Acad. Sci. USA 96, 5182–5187 (1999).
   PubMed Web of Science ®Google Scholar
• Weissleder R. Molecular imaging: exploring the next frontier. Radiology 212, 609–614 (1999).
   PubMedGoogle Scholar
• Gutierrez F, Brown J, Mirowitz S. Cardiovascular Magnetic Resonance Imaging. Mosby Year Book, St. Louis, USA (1992).
   Google Scholar
• Nelson KL, Runge VM. Basic principles of MR contrast. Top. Magn. Reson. Imaging 7, 124–136 (1995).
   PubMedGoogle Scholar
• Semelka RC, Lee JK, Worawattanakul S, Noone TC, Patt RH, Ascher SM. Sequential use of ferumoxide particles and gadolinium chelate for the evaluation of focal liver lesions on MRI. J. Magn. Reson. Imaging 8, 670–674 (1998).
   Google Scholar
• Scott J, Ward J, Guthrie JA, Wilson D, Robinson PJ. MRI of liver: a comparison of CNR enhancement using high dose and low dose ferumoxide infusion in patients with colorectal liver metastases. Magn. Reson. Imaging 18, 297–303 (2000).
   Google Scholar
• Nakayama M, Yamashita Y, Mitsuzaki K et al. Improved tissue characterization of focal liver lesions with ferumoxide-enhanced T1 and T2-weighted MR imaging. J. Magn. Reson. Imaging 11, 647–654 (2000).
   PubMedGoogle Scholar
• Imam K, Bluemke DA. MR imaging in the evaluation of hepatic metastases. Magn. Reson. Imaging Clin. N. Am. 8, 741–756 (2000).
   Google Scholar
• Kato H, Kanematsu M, Kondo H et al. Ferumoxide-enhanced MR imaging of hepatocellular carcinoma: correlation with histologic tumor grade and tumor vascularity. J. Magn. Reson. Imaging 19, 76–81 (2004).
   Google Scholar
• Araki T. SPIO-MRI in the detection of hepatocellular carcinoma. J. Gastroenterol. 35, 874–876 (2000).
   Google Scholar
• Nakamura H, Ito N, Kotake F, Mizokami Y, Matsuoka T. Tumor-detecting capacity and clinical usefulness of SPIO-MRI in patients with hepatocellular carcinoma. J. Gastroenterol. 35, 849–855 (2000).
   Google Scholar
• Stiskal M, Schwickert HC, Demsar F et al. Contrast enhancement in experimental radiation-induced liver injury: comparison of hepatocellular and reticuloendothelial particulate contrast agents. J. Magn. Reson. Imaging 6, 286–290 (1996).
   PubMed Web of Science ®Google Scholar
• Weissleder R, Reimer P, Lee AS, Wittenberg J, Brady TJ. MR receptor imaging: ultrasmall iron oxide particles targeted to asialoglycoprotein receptors. AJR Am. J. Roentgenol. 155, 1161–1167 (1990).
   PubMed Web of Science ®Google Scholar
• Reimer P, Weissleder R, Brady TJ et al. Experimental hepatocellular carcinoma: MR receptor imaging. Radiology 180, 641–645 (1991).
   Google Scholar
• Litovsky S, Madjid M, Zarrabi A, Casscells SW, Willerson JT, Naghavi M. Superparamagnetic iron oxide-based method for quantifying recruitment of monocytes to mouse atherosclerotic lesions in vivo: enhancement by tissue necrosis factor-α, interleukin-1β, and interferon-γ. Circulation 107, 1545–1549 (2003).
   PubMed Web of Science ®Google Scholar
• Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, Josephson L. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 175, 489–493 (1990).
   PubMed Web of Science ®Google Scholar
• Renkin EM. Multiple pathways of capillary permeability. Circulation Res. 41, 735–743 (1977).
   PubMed Web of Science ®Google Scholar
• van Hinsbergh VWM. Endothelial permeability for macromolecules: mechanistic aspects of pathophysiological modulation. Arterioscler. Thromb. Vasc. Biol. 17, 1018–1023 (1997).
   PubMedGoogle Scholar
• Ruehm SG, Corot C, Vogt P, Kolb S, Debatin JF. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation 103, 415–422 (2001).
   PubMed Web of Science ®Google Scholar
• Kanno S, Wu YJ, Lee PC et al. Macrophage accumulation associated with rat cardiac allograft rejection detected by magnetic resonance imaging with ultrasmall superparamagnetic iron oxide particles. Circulation 104, 934–938 (2001).
   PubMedGoogle Scholar
• Kooi ME, Cappendijk VC, Cleutjens KB et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 107, 2453–2458 (2003).
   PubMed Web of Science ®Google Scholar
• Leenders W, Kusters B, Pikkemaat J et al. Vascular endothelial growth factor-A determines detectability of experimental melanoma brain metastasis in GD-DTPA-enhanced MRI. Int. J. Cancer 105, 437–434 (2003).
   Google Scholar
• Turetschek K, Roberts TP, Floyd E et al. Tumor microvascular characterization using ultrasmall superparamagnetic iron oxide particles (USPIO) in an experimental breast cancer model. J. Magn. Reson. Imaging 13, 882–888 (2001).
   Google Scholar
• Turetschek K, Huber S, Floyd E et al. MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation. Radiology 218, 562–569 (2001).
   PubMed Web of Science ®Google Scholar
• Gellissen J, Axmann Ch, Prescher A, Bohndorf K, Lodemann KP. Extra- and intracellular accumulation of ultrasmall superparamagnetic iron oxides (USPIO) in experimentally induced abscesses of the peripheral soft tissues and their effects on magnetic resonance imaging. Magn. Reson. Imaging 17, 557–567 (1999).
   Google Scholar
• Saleh A, Schroeter M, Jonkmanns C, Hartung HP, Modder U, Jander S. In vivo MRI of brain inflammation in human ischaemic stroke. Brain 127, 1670–1677 (2004).
   PubMed Web of Science ®Google Scholar
• Weissleder R, Lee AS, Khaw BA, Shen T, Brady TJ. Antimyosin-labeled monocrystalline iron oxide allows detection of myocardial infarct: MR antibody imaging. Radiology 182, 381–385 (1992).
   PubMed Web of Science ®Google Scholar
• Weissleder R, Moore A, Mahmood U et al. In vivo magnetic resonance imaging of transgenic expression. Nature Med. 6, 351–355 (2000).
   PubMedGoogle Scholar
• Dunn JF, Roche MA, Springett R et al. Monitoring angiogenesis in brain using steady-state quantification of δ-R2 with MION infusion. Magn. Reson. Med. 51, 55–61 (2004).
   PubMed Web of Science ®Google Scholar
• Wu EX, Tang H, Wong KK, Wang J. Mapping cyclic change of regional myocardial blood volume using steady-state susceptibility effect of iron oxide nanoparticles. J. Magn. Reson. Imaging 19, 50–58 (2004).
   PubMed Web of Science ®Google Scholar
• Hogemann D, Josephson L, Weissleder R, Basilion JP. Improvement of MRI probes to allow efficient detection of gene expression. Bioconjug. Chem. 11, 941–946 (2000).
   Web of Science ®Google Scholar
• Kang HW, Josephson L, Petrovsky A, Weissleder R, Bogdanov A Jr. Magnetic resonance imaging of inducible E-selectin expression in human endothelial cell culture. Bioconjug. Chem. 13, 122–127 (2002).
   PubMed Web of Science ®Google Scholar
• Koch AM, Reynolds F, Kircher MF, Merkle HP, Weissleder R, Josephson L. Uptake and metabolism of a dual fluorochrome Tat-nanoparticle in HeLa cells. Bioconjug. Chem.14, 1115–1121 (2003).
   PubMed Web of Science ®Google Scholar
• Josephson L, Tung CH, Moore A, Weissleder R. High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug. Chem.10, 186–191 (1999).
   PubMed Web of Science ®Google Scholar
• Dodd CH, Hsu HC, Chu WJ et al. Normal T-cell response and in vivo magnetic resonance imaging of T-cells loaded with HIV transactivator-peptide-derived superparamagnetic nanoparticles. J. Immunol. Methods 256, 89–105 (2001).
   PubMed Web of Science ®Google Scholar
• Lewin M, Carlesso N, Tung CH et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nature Biotechnol. 18, 410–414 (2000).
   PubMed Web of Science ®Google Scholar
• Schellenberger EA, Bogdanov A Jr, Hogemann D, Tait J, Weissleder R, Josephson L. Annexin V-Clio: a nanoparticle for detecting apoptosis by MRI. Mol. Imaging 1, 102–107 (2002).
   PubMed Web of Science ®Google Scholar
• Artemov D, Mori N, Okollie B, Bhujwalla ZM. MR Molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn. Reson. Med. 49, 403–408 (2003).
   PubMed Web of Science ®Google Scholar
• Moffat BA, Reddy GR, McConville P et al. A novel polyacrylamide magnetic nanoparticle contrast agent for molecular imaging using MRI. Mol. Imaging 2, 324–332 (2003).
   PubMedGoogle Scholar
• Tung C-H, Mahmood U, Bredow S, Weissleder R. In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. Cancer Res. 60, 4953–4958 (2000).
   PubMedGoogle Scholar
• Bremer C, Tung C-H, Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nature Med. 7, 655–656 (2001).
   Google Scholar
• Mahmood U, Tung C-H, Bogdanov A Jr, Weissleder R. Near-infrared optical imaging of protease activity for tumor detection. Radiology 213, 866–870 (1999).
   PubMedGoogle Scholar
• Ntziachristos V, Weissleder R. Experimental three-dimensional fluorescence reconstruction of diffuse media by use of a normalized Born approximation. Optics Letters 26, 893–895 (2001).
   Google Scholar
• Ntziachristos V, Yodh AG, Schnall M, Chance B. Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement. Proc. Natl Acad. Sci. USA 97, 2767–2772 (2000).
   PubMed Web of Science ®Google Scholar
• Josephson L, Kirchner MF, Mahmood U, Tang Y, Weissleder R. Near-infrared fluorescent nanoparticles as combined MR/optical imaging probes. Bioconjug. Chem.13, 554–560 (2002).
   PubMed Web of Science ®Google Scholar
• Kircher MF, Mahmood U, King RS, Weissleder R, Josephson L. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res. 63, 8122–8125 (2003).
   PubMed Web of Science ®Google Scholar
• Bulte JW, Zhang S, van Gelderen P et al. Neurotransplantation of magnetically labeled oligodendrocyte progenitors: magnetic resonance tracking of cell migration and myelination. Proc. Natl Acad. Sci. USA 96, 15256–15261 (1999).
   Google Scholar
• Frank JA, Miller BR, Arbab AS et al. Clinically applicable labeling of mammalian and stem cells by combining superparamagnetic iron oxides and transfection agents. Radiology 228, 480–487 (2003).
   PubMed Web of Science ®Google Scholar
• Bulte JWM, Douglas T, Witwer B et al. Monitoring stem cell therapy in vivo using magnetodendrimers as a new class of cellular MR contrast agents. Acad. Radiol. 9, S332–S335 (2002).
   Google Scholar
• Kircher MF, Allport JR, Graves E et al. In vivo High resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors Cancer Res. 63, 6838–6846 (2003).
   Google Scholar
• Wunderbaldinger P, Josephson L, Weissleder R. Tat peptide directs enhanced clearance and hepatic permeability of magnetic nanoparticles. Bioconjug. Chem.13, 264–268 (2002).
   PubMed Web of Science ®Google Scholar
• Kraitchman DL, Heldman AW, Atalar E et al. In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. Circulation 107, 2290–2293 (2003).
   PubMed Web of Science ®Google Scholar
• Karmarkar PV, Kraitchman DL, Izbudak I et al. MR-trackable intramyocardial injection catheter. Magn. Reson. Med. 51, 1163–1172 (2004).
   PubMed Web of Science ®Google Scholar
• Lanza GM, Wallace KD, Scott MJ et al. A novel site-targeted ultrasonic contrast agent with broad biomedical application. Circulation 94, 3334–3340 (1996).
   PubMed Web of Science ®Google Scholar
• Lanza GM, Abendschein DR, Hall CS et al. In vivo molecular imaging of stretch-induced tissue factor in carotid arteries with ligand-targeted nanoparticles. J. Am. Soc. Echocardiog. 13, 608–614 (2000).
   PubMed Web of Science ®Google Scholar
• Flacke S, Fischer S, Scott MJ et al. Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation 104, 1280–1285 (2001).
   PubMed Web of Science ®Google Scholar
• Lanza GM, Lorenz CH, Fischer SE et al. Enhanced detection of thrombi with a novel fibrin-targeted magnetic resonance imaging agent. Academic Radiology 5(Suppl. 1), S173–S176 (1998).
   PubMed Web of Science ®Google Scholar
• Winter PM, Caruthers SD, Yu X et al. Improved molecular imaging contrast agent for detection of human thrombus. Magn. Reson. Med. 50, 411–416 (2003).
   PubMed Web of Science ®Google Scholar
• Morawski AM, Winter P, Crowder KC et al. Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magn. Reson. Med. 51, 480–486 (2004).
   PubMed Web of Science ®Google Scholar
• Lanza GM, Yu X, Winter PM et al. Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation 106, 2842–2847 (2002).
   PubMed Web of Science ®Google Scholar
• Winter PM, Caruthers SD, Kassner A et al. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel ανβ3-targeted nanoparticle and 1.5 Tesla magnetic resonance imaging. Cancer Res. 63, 5838–5843 (2003).
   PubMed Web of Science ®Google Scholar
• Winter PM, Morawski AM, Caruthers SD et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with ανβ3-integrin-targeted nanoparticles. Circulation 108, 2270–2274 (2003).
   PubMed Web of Science ®Google Scholar
• Bangham AD. Membrane models with phospholipids. Prog. Biophys. Mol. Biol. 18, 29–95 (1968).
   PubMedGoogle Scholar
• Hope MJ, Bally MB, Mayer LD, Janoff AS, Cullis PR. Generation of multilamellar and unilamellar phospholipid vesicles. Chem. Phys. Lipids 40, 89–107 (1986).
   Web of Science ®Google Scholar
• Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl Acad. Sci. USA 85, 6949–6953 (1988).
   PubMed Web of Science ®Google Scholar
• Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochem. Biophys. Acta 1113, 171–199 (1992).
   PubMed Web of Science ®Google Scholar
• Ulrich AS. Biophysical aspects of using liposomes as delivery vehicles. Biosci. Rep. 22, 129–150 (2002).
   Google Scholar
• Lokling K-E, Skurtveit R, Dyrstad K, Klaveness J, Fossheim SL. Tuning the MR properties of blood-stable pH-responsive paramagnetic liposomes. Int. J. Pharmaceutics 274, 75–83 (2004).
   Google Scholar
• Mamot C, Nguyen JB, Pourdehnad M et al. Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. J. Neuro-Oncol. 68, 1–9 (2004).
   PubMed Web of Science ®Google Scholar
• Saito R, Bringas JR, McKnight TR et al. Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res. 64, 2572–2579 (2004).
   PubMed Web of Science ®Google Scholar
• Viglianti BL, Abraham SA, Michelich CR et al. In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery. Magn. Reson. Imaging 51, 1153–1162 (2004).
   Google Scholar
• Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. Detection of tumor angiogenesis in vivo by ανβ3-targeted magnetic resonance imaging. Nature Med. 4, 623–626 (1998).
   PubMed Web of Science ®Google Scholar
• Hood JD, Bednarski M, Frausto R et al. Tumor regression by targeted gene delivery to the neovasculature. Science 296, 2404–2407 (2002).
   PubMed Web of Science ®Google Scholar
• Wilson SR. Biological applications of fullerene derivatives: a brief overview. In: The Fullerene Handbook. Kadish K, Ruoff R, (Eds), Wiley, NY, USA, 437–465 (2000).
   Google Scholar
• Bosi S, Da Ros T, Spalluto G, Prato M. Fullerene derivatives: an attractive tool for biological applications. Eur. J. Med. Chem. 38, 913–923 (2003).
   PubMed Web of Science ®Google Scholar
• Qingnuan L, Yan X, Xiaodong Z et al. Preparation of (99m)Tc-C(60)(OH)(x) and its biodistribution studies. Nuclear Med. Biol. 29, 707–710 (2002).
   PubMed Web of Science ®Google Scholar
• Mikawa M, Kato H, Okamura M et al. Paramagnetic water-soluble metallofullerenes having the highest relaxivity for MRI contrast agents. Bioconjug. Chem.12, 510–514 (2001).
   PubMed Web of Science ®Google Scholar
• Bolskar RD, Benedetto AF, Husebo LO et al. First soluble M@C60 derivatives provide enhanced access to metallofullerenes and permit in vivo evaluation of Gd@C60 [C(COOH)2]10 as a MRI contrast agent. J. Am. Chem. Soc. 125, 5471–5478 (2003).
   PubMed Web of Science ®Google Scholar
• Boas U, Heegaard PMH. Dendrimers in drug research. Chem. Soc. Rev. 33, 43–63 (2004).
   PubMed Web of Science ®Google Scholar
• Misselwitz B, Schmitt-Willich H, Ebert W, Frenzel T, Weinmann HJ. Pharmacokinetics of Gadomer-17, a new dendritic magnetic contrast agent. Magma 12, 128–134 (2001).
   PubMedGoogle Scholar
• Fink C, Kiessling F, Bock M et al. High-resolution three-dimensional MR angiography of rodent tumors: morphologic characterization of intratumoral vasculature. J. Magn. Reson. Imaging 18, 59–65 (2003).
   PubMed Web of Science ®Google Scholar
• Staats G, Spuntrup E, Bucker A et al. Interstitial T1-weighted MR lymph fistulography with Gadomer-17 in an experimental animal model. ROFO-Fortschritte auf dem Gebiet der Rontgenstrahlen und Bildgebenden Verfahren 175, 275–281 (2003).
   Google Scholar
• Torchia MG, Misselwitz B. Combined MR lymphangiography and MR imaging-guided needle localization of sentinel lymph nodes using Gadomer-17. Am. J. Roentgenol. 179, 1561–1565 (2002).
   Google Scholar
• Misselwitz B, Schmitt-Willich H, Michaelis M, Oellinger JJ. Interstitial magnetic resonance lymphography using a polymeric T1 contrast agent: initial experience with Gadomer-17. Invest. Radiol. 37, 146–151 (2002).
   Google Scholar
• Sato N, Kobayashi H, Hiraga A et al. Pharmacokinetics and enhancement patterns of macromolecular MR contrast agents with various sizes of polyamidoamine dendrimer cores. Magn. Reson. Med. 46, 1169–1173 (2001).
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Sato N, Hiraga A et al. 3D-micro-MR angiography of mice using macromolecular MR contrast agents with polyamidoamine dendrimer core with reference to their pharmacokinetic properties. Magn. Reson. Med. 45, 454–460 (2001).
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Wu C, Kim MK, Paik CH, Carrasquillo JA, Brechbiel MW. Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with antitac monoclonal antibody. Bioconjug. Chem.10, 103–111 (1999).
   PubMed Web of Science ®Google Scholar
• Wiseman GA, Kornmehl E, Leigh B et al. Radiation dosimetry results and safety correlations from 90 Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin’s lymphoma: combined data from 4 clinical trials. J. Nucl. Med. 44, 465–474 (2003).
   PubMed Web of Science ®Google Scholar
• Quintana A, Raczka E, Piehler L et al. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm. Res. 19, 1310–1316 (2002).
   PubMed Web of Science ®Google Scholar
• Malik N, Wiwattanapatapee R, Klopsch R et al. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J. Control Release 65, 133–148 (2000).
   PubMed Web of Science ®Google Scholar
• Bourne N, Stanberry LR, Kern ER, Holan G, Matthews B, Bernstein DI. Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection. Antimicrob. Agents Chemother. 44, 2471–2474 (2000).
   PubMed Web of Science ®Google Scholar
• Ihre HR, Padilla De Jesus OL, Szoka FCJ, Frechet JMJ. Polyester dendritic systems for drug delivery applications: design, synthesis, and characterization. Bioconjug. Chem.13, 443–452 (2002).
   PubMed Web of Science ®Google Scholar
• Padilla De Jesus OL, Ihre HR, Gagne L, Frechet JMJ, Szoka FCJ. Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation. Bioconjug. Chem.13, 453–461 (2002).
   PubMed Web of Science ®Google Scholar